Navigation Links
Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/23/2007

BOULDER, Colo., Oct. 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH), is presenting data today at the AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference is being held October 22-26, 2007 at the Moscone Convention Center, San Francisco, Calif.

In a poster session, Tapestry investigators will be discussing data from preclinical studies of TPI 287, the company's proprietary next-generation taxane for the treatment of multiple cancer indications, on Tuesday, October 23, 2007 from 12:30 - 2:30 PM Pacific Time in the Drug Resistance Session A:

Poster #192: "TPI 287, A Next Generation Taxane Derivative, Functionally

Modulates MDR1 P-glycoprotein Drug Transport Pump and is Active in

Resistant Tumor Cells"

The poster outlines a number of different assays confirming Tapestry's observation that its lead drug candidate TPI 287 is less sensitive in a variety of cancer cell lines to MDR1 mediated efflux than other approved taxanes. MDR1 mediated drug efflux may be a primary cause of resistance to chemotherapy with taxanes.

Additionally, TPI 287 is retained at higher levels in MDR1 expressing cell lines than either paclitaxel or IDN 5109, another taxane in development purported to be active in MDR1 expressing tumors. In addition, TPI 287 has demonstrated tumor growth inhibition when delivered orally in subcutaneous mouse xenograft models of both pancreatic cancer and glioblastoma multiforme (GBM). Tapestry has Phase 2 studies underway for TPI 287 in pancreatic and prostate cancer. The Company plans to evaluate TPI 287 in a Phase 2 study in GBM. A copy of the poster is available on Tapestry's website at '/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ANTON, Calif., Dec. 2 Ro...hat the United States Food & Drug Administrati...ts licensed nucleic acid test, to screen source pl...ations. The test, called the cobas® TaqScreen...a qualitative, in-vitro test for the simultaneous,...
(Date:12/2/2009)..., EAST HANOVER, N.J., Dec. 2 Nova...te-breaking presentation on Tasigna® (nilotin...eukemia, demonstrate the strength of the company,s...ients. ,, The new data, at the 51st American S...sition, highlight the company,s current therapies ...
(Date:12/1/2009)...O BEACH, Calif., Dec. 1 Reproducti...ective Single Embryo Transfer (eSET) Encouragement...ents with good embryo quality and a good prognosis...ins by transferring a single embryo. ,, The big...ay is reducing the number of multiple pregnancies,...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2Supply Chain Council Announces New Board of Directors and Officers 9218 1UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 1UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 2How to De Stress a Recession Riddled Life 51398 1How to De Stress a Recession Riddled Life 51398 2How to De Stress a Recession Riddled Life 51398 3
... review programs need more,money, WASHINGTON, Marc...te by the Alzheimer,s Association shows that more ...mer,s disease -- a 10,percent growth over previous...e in the coming decades unless new treatments and ..., The new numbers re-emphasize the need for a stro...
... in Peer-Review Journal,Respiratory Medicine, SAN ...oalition,for Pulmonary Fibrosis (CPF) today announ...uestionnaire, considered one of the,largest databa...pathic pulmonary fibrosis (IPF) in the United Stat...lication is an,internationally-renowned, peer-revi...
Other Medicine Technology:Alzheimer's Growth Shows Need for Increased FDA Funding 2Alzheimer's Growth Shows Need for Increased FDA Funding 3Medical Journal Publishes First Large-Scale Survey Revealing,Experiences of IPF Patients 2Medical Journal Publishes First Large-Scale Survey Revealing,Experiences of IPF Patients 3
(Date:12/2/2009)...ng by federal government ends nine months of obstr...2 More than 2,300 healt... facilities across Southern California will soon v... of Healthcare Workers (NUHW). ,, A majority of...ary, but SEIU delayed the election by filing frivo...
(Date:12/2/2009)...ficial congress of the European Association of Ech...ropean Society of Cardiology, where techniques of ... , New case reports will be presented at this y...ing the role of this new technology. , Now, wit... is likely that non-invasive imaging will gain mor...
(Date:12/2/2009)... National Race Series to increase awareness of pro... the importance of early detection , ... Men, women, families, friends and neighbors &ndas...rticipate in the Rudolph Ramble 5K. The Rudolph R...es , which was launched by the Prostate Condition...
(Date:12/2/2009)..., Dec. 2 Pro-abortion a...ber 2 in their campaign against the U.S. House bil...ans United for Life President and CEO Charmaine Yo...rtion lobby,s effort to expand taxpayer funding of...h care, the feminist groups and the abortion lobby...
(Date:12/2/2009)...SAS CITY, Mo., Dec. 2 Lockton Ben...nsive, practical view on proposed health reform le... http://www.newscom.com/cgi-bin/prnh/20090415/CG9..., and ugly in the legislation, according to Ed Fen...fit Group,s Compliance Services Division and Loc...
Breaking Medicine News(10 mins):Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2Health News:Media alert: EUROECHO 2009 2Health News:PACE Race Returns with Denver's Rudolph Ramble 2Health News:PACE Race Returns with Denver's Rudolph Ramble 3Health News:PACE Race Returns with Denver's Rudolph Ramble 4Health News:Lockton Outlines Implications of Proposed Health Reform Plans 2
... University of Minnesota Medical School researcher... could affect history// has been made at the locat...s been deciphered. Ataxia is an incurable degen... the protein, a-III spectrin which plays an import...
... An ambulance service will be established in the I...s with the object of providing patients with criti...ion, and its nerve center will be the Hinduja Hosp...of the network, which has the blessings of the Mah...
... A blue baby from Pakistan was given a new lease o... the Sri M.G. Ramachandra Medical College and Hosp...ring from a restricted flow of oxygenated blood. H...ed the surgery. The baby, accompanied by fa...
... As many as 50% of the teenaged girls in the UK ar...rding to a research conducted by the Food Standard...s are reported to be as young as 13 years. The fin...ittle as possible,’ while ten per cent said they a...
... A study published in the Journal of Infectious Di...valence of Staphylococcus aureus in nasal samples,... a causative factor in a majority of the hospital ...ections in the US. About 1% of the nasal sam...
... An investigation conducted by the Scotsman has re... access emergency dental care, particularly during...rtment had drawn up an emergency care plan which i...s highlands, with 10% of the population having to ...
Other Medicine News:Health News:Ataxia: a problematic disease's gene deciphered 2Health News:Mumbai To Get Emergency Ambulance Service 2Health News:90 Million Americans Harbor Drug Resistant Bacteria Inside Their Nose 2
Advance Posterior Stabilized Total Knee Systems
Alpina Total Knee Prosthesis
Scorpio CR Knee, cruciate retaining single axis
...UC-Plus Solution knee is the state of the art prod...nt. Geometry of the articular surfaces does not re...mical variations, and achieves a wide area of cont...ge, uninterrupted pockets of cement create a homog...
Medicine Products: